Title: Health Technology Assessment in Cancer: Driving Efficiency and Efficacy, but at What Cost?

Patrick G. Johnston, MD, PhD
President and Vice-Chancellor, The Queen’s University
Belfast, UK

Speaker

Yasuhiro Fujiwara, MD, PhD
Director-General, Strategic Planning Bureau of the National Cancer Center, Japan

Chairman

Patrick G. Johnston, MD, PhD

Profile

Prof. Johnston is President and Vice-Chancellor, Queen’s University Belfast. Prof. Johnston has published over 250 research articles and 5 books, and holds over 25 patents. His research is focused on cellular signalling pathways in human colorectal cancer, primarily related to molecular targeted cancer, therapeutics, personalised cancer medicine and mechanisms of drug resistance.

He received his medical degree with distinction from University College Dublin in 1982, followed by his PhD in Medicine in 1988. He obtained a fellowship at the National Cancer Institute (NCI USA) in 1987 where he pursued further clinical training in medical oncology and doctoral studies in molecular pharmacology, drug resistance and drug development.
In 1997 he moved to Queen’s University Belfast as Professor of Oncology and became Director of the Centre for Cancer Research and Cell Biology in 2004. He became Dean of the School of Medicine, Dentistry and Biomedical Sciences at Queen’s University Belfast in 2007. In 2014 he has become vice-chancellor and President of Queen’s University Belfast.

He has been awarded many national and international awards, is a Fellow of the Academy of Medical Sciences, and sits on a number of influential national and international scientific and government advisory boards. He was appointed chair of the Translational Research Group of the Medical Research Council (MRC) in 2012. He received the 2013 International Bob Pinedo Cancer Care Prize. He also serves on the Cancer Research UK (CR-UK) science executive/advisory board. Outside his academic work, Prof Johnston is a founder of Northern-Ireland based Almac Diagnostics and the Society for Translational Oncology which is headquartered in Durham, North Carolina.

Recent Publications (CHAAO selected)


